Matsumoto Katsumi, Sumita Shin-ichi, Ishikawa Toshiyuki, Matsushita Kohei, Kobayashi Tsukasa, Ohkusu Yasuo, Yamakawa Yohei, Nakagawa Takeshi, Nakazawa Ichiroh, Mochida Yasuyuki, Ebina Toshiaki, Uchino Kazuaki, Kimura Kazuo, Umemura Satoshi
Second Department of Internal Medicine, Yokohama City University, School of Medicine, Fukuura 3-9, Kanazawa-ku, Yokohama 236-0004.
J Cardiol. 2003 Nov;42(5):227-34.
A 56-year-old man with Brugada syndrome presented with ventricular fibrillation induced by administration of pilsicainide. He had syncope at age 46 years, and his uncle suddenly died of unknown cause. He had taken pilsicainide (150 mg/day) for paroxysmal atrial fibrillation, and suffered from syncope due to ventricular fibrillation. Coved type ST elevation was observed in the V1 lead, and saddle back type ST elevation was observed in the V2 lead. The ST elevation gradually recovered after stopping pilsicainide therapy. No structural heart disease was found. After intravenous injection of pilsicainide, the ST segment elevated in the V1 and V2 leads. Ventricular fibrillation was induced by triple extrastimulation at the right ventricular apex. The diagnosis was Brugada syndrome, and a cardioverter-defibrillator was implanted. Brugada syndrome should be considered before administering pilsicainide.
一名56岁的布加综合征男性患者,因服用吡西卡尼诱发室颤。他46岁时曾发生晕厥,其叔叔不明原因突然死亡。他因阵发性房颤服用吡西卡尼(150毫克/天),并因室颤发生晕厥。V1导联观察到穹窿型ST段抬高,V2导联观察到鞍背型ST段抬高。停用吡西卡尼治疗后,ST段抬高逐渐恢复。未发现结构性心脏病。静脉注射吡西卡尼后,V1和V2导联ST段抬高。在右心室尖部进行三重额外刺激诱发了室颤。诊断为布加综合征,植入了心脏复律除颤器。在使用吡西卡尼之前应考虑布加综合征。